Anti-emetic Drugs in Oncogynecology
Jirsová S.1, Cibula D.1, Eretová V.1, Freitag P.1, Jančárková N.1, Hejlová P.2, Mareš P.3, Pavlišta D.1, Živný J.1
1Gynekologicko-porodnická klinika 1. LF UK a VFN v Praze, přednosta prof. MUDr. J. Živný, DrSc. 2Gynekologicko-porodnické oddělení NsP Mělník, primář MUDr. J. Zmrhal, CSc. 3Onkologická klinika 1. LF UK a VFN v Praze, přednosta doc. MUDr. L. Petruželka, CSc. |
|
Summary:
Objective: The authors present a survey of available pharmacological possibilities of treatment of
nausea and vomiting aimed at their application in oncological therapy of gynecological neoplastic
diseases.
Type of the study: A review article.
Name andAddress of the Institution: Gynecological-Obstetrical Clinic,FirstMedicalFaculty, Charles
University and General Faculty Hospital, Praha.
Subject and Method of the Study: A survey of published data fromthe Czech and foreign professional
literature.
Conclusion: 5-HT3 receptor antagonists take up the most important position in the antiemetic
treatment of oncological patients. They efficiently preventand treatvomiting induced by anticancer
drugs with high and very high emetogenic effect. They have been used as monotherapy or in
combination with corticoids. In the treatment of nausea and vomiting or vomiting induced by anticancer drugs with medium or light emetogenic effect, antiemetic preparations from the corticoid
series and dopamine receptor antagonists may be recommended. In the treatment of anticipation
vomiting, benzodiazepines are indicated for their anxiolytic and psychosedative influence.
Key words:
antiemetics, estrones, 5-HT3 antagonists
|